Is electroacupuncture safe and effective for treatment of stress urinary incontinence in women? A systematic review and meta-analysis

Xiuhua Lai¹, Jiapeng Zhang², Jing Chen³, Cuiwei Lai¹ and Chunping Huang¹

Abstract
Objective: Stress urinary incontinence (SUI) is prevalent worldwide, particularly among elderly women. Although electroacupuncture (EA) has been accepted by many patients and physicians in Asia, its efficacy for SUI has not been evaluated scientifically and systematically. We aimed to conduct a systematic evaluation of the efficacy and safety of EA treatment for women with SUI.

Methods: We retrieved publications up to February 2019 from seven databases. Randomized controlled trials for women with SUI treated by EA were included. Therapeutic effect, 1-hour urine leakage and International Consultation on Incontinence Questionnaire – Short Form (ICIQ-SF) scores were the primary outcomes. The Cochrane Collection's RevMan 5.3 software was used to pool data.

Results: The 15 included articles demonstrated that EA for SUI was effective (odds ratio [OR], confidence interval [CI] = 5.64, 4.19–7.59; I² = 22%). ICIQ-SF scores increased (standard mean difference, CI = −0.48, −0.62 to −0.33; I² = 32%) and 1-hour urine leakage decreased (OR, CI = −4.14, −4.96 to −3.33; I² = 78%) in patients undergoing EA compared with those receiving sham EA, physical exercise or medication.

Conclusion: EA for women with SUI exhibited significant efficacy and safety for key outcomes.

¹Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, Guangdong, P. R. China
²Medical College of Jiaying University, Meizhou, Guangdong, P. R. China
³Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, P. R. China

Corresponding author:
Xiuhua Lai, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, Huangtang Road, Meijiang District, Meizhou, Guangdong 514031, P. R. China.
Email: 344586283@qq.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords
Stress urinary incontinence, electroacupuncture, systematic review, meta-analysis, sham acupuncture, medication, physical exercise, China

Date received: 25 September 2019; accepted: 9 July 2020

Introduction
Stress urinary incontinence (SUI) is defined by the International Continence Society as an involuntary loss of urine on physical exertion, sneezing or coughing.\(^1\) Epidemiological studies have demonstrated that SUI is a common health problem worldwide, and is experienced by 23\% to 45\% of the female population. The prevalence in the United States is 24.8\%\(^2\) and that in China is 18.9\%\(^3,4\)

Although SUI is not life threatening, it negatively affects the physical health and social and psychological well-being of patients, causing reduced quality of life. Moreover, SUI is associated with complications, including diabetes, hyperlipidaemia and chronic kidney disease, which can be a burden for patients’ families.\(^5\)

A few effective therapies for SUI are available, including pelvic floor muscle training (PFMT), which is generally regarded as the first line treatment for SUI and is recommended by the American Urological Association;\(^3\) however, PFMT must be practised for a long time and adherence rates are negatively correlated with time.\(^6,7\) In addition, PFMT training techniques are difficult to master. Surgery can be effective for patients with severe SUI; however, the potential complications, which include pain, infection and dysuria following surgery, are unacceptable for patients with SUI. Hence, effective and safe treatments for patients with SUI are urgently required.

Acupuncture has been practised for over 2500 years in China, and includes a range of techniques, such as manual acupuncture (MA), scalp acupuncture, electroacupuncture (EA) and body acupuncture. EA is particularly recommended by the National Institutes of Health as a supplementary or alternative treatment for many diseases, including SUI. A 2017 randomized controlled trial (RCT) demonstrated a clinically significant reduction in urine leakage and improved quality of life in patients administered EA compared with those receiving sham EA treatment.\(^8\) Several clinical studies have suggested that acupuncture, including EA, can effectively treat SUI by improving acetic-acid induced bladder irritation through inhibition of capsaicin sensitivity.\(^9,10\) The results of one meta-analysis of studies of patients with urinary calculus showed that the acupuncture treatment group had a higher total effective rate and cure rate and a lower urinary calculi excretion rate than the drug treatment group.\(^11\)

Nevertheless, the status of current evidence means that the efficacy of acupuncture for SUI remains controversial. For example, a 2013 meta-analysis that investigated standard interventions, including MA, EA and other acupuncture methods, showed that acupuncture had an uncertain curative effect on SUI.\(^10\) However, EA and MA are not interchangeable. Therefore, research must differentiate between the effects of these two methods; studies that mix MA and EA are not homogeneous.\(^10\)
There have been many clinical studies and reports on the effects of EA treatment in patients with SUI; however, meta-analyses evaluating the effectiveness and safety of this type of therapy are lacking. Here, we aimed to assess the efficacy and safety of EA for SUI and provide high quality evidence for its clinical therapeutic effects in this context. This study provides detailed evidence regarding the safety and efficacy of EA therapy for SUI.

Methods
This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and was registered in the International Prospective Register of Systematic Reviews (number: CRD42018112689).

Search strategy
We systematically searched databases for relevant studies published up to February 2019, including three international and four Chinese databases: PubMed, the Cochrane Library, Web of Science, China National Knowledge Infrastructure Database (CNKI), Chinese Biological Medicine Database (CBM), VIP (Database for Chinese Technical Periodicals) and WanFang Digital Periodicals Database (WFDP). The search terms used related to acupuncture (e.g. acupuncture, electroacupuncture, needle, needles) and SUI (e.g. stress urinary incontinence, stress incontinence). Only papers originally written in English or Chinese were considered. In addition, included papers were limited to clinical trials, RCTs and National Institutes of Health RCTs.

We used the following combined text for searches: ‘((acupuncture OR acup* OR electroacupuncture OR electroacup*) AND (stress urinary incontinence OR stress incontinence OR uroclepsia OR incontinentia urinae))’. Databases were searched for publications indexed between their inception and February 2019.

Inclusion criteria
Studies that met the following criteria were included.

Types of participants. All studies needed to include women who met the criteria for the standardized diagnosis of SUI; within a trial, the control group had to have received the same baseline interventions as the EA group. Studies were excluded if they contained patients with serious systemic or neurologic disease or urinary system infection; patients who had undergone preoperative radiotherapy or chemotherapy; patients who had serious conditions, such as cardiovascular, liver, kidney and haematopoietic system disease (because they may have had an unusual medical history); or patients who refused EA treatment.

Types of studies. RCTs of EA as a treatment option for SUI were included. Nonrandomized trials, quasi-experimental studies, observational studies, animal studies, qualitative studies, letters, news articles, editorials and commentaries were also excluded. The titles and abstracts of the searched articles were read by a single primary researcher (JC) who had trained in literature searching and systematic reviewing for 3 years. If the articles were not written in English, we primarily reviewed them using their abstracts, which were translated into English prior to screening by a commercial service (if we experienced difficulty with language comprehension). Articles for potential inclusion were checked by two independent reviewers (ZY, JC).
Types of intervention/control groups. Treatment groups received EA; there was no limit on the needle material, choice of acupoints, treatment methods, needle retention time or course of treatment. Control groups received internationally recognized therapies, such as PFMT or Western medicine, or sham EA therapy.

Types of outcome measures. The primary outcome was the therapeutic effect. The secondary outcomes were scores on the International Consultation on Incontinence Questionnaire – Short Form (ICIQ-SF),13 the change from baseline in the amount of urine leakage as measured by the 1-hour pad test, and the frequency and nature of adverse events.

Data extraction
The titles and abstracts of all citations identified in the search were imported into Endnote, Version X6 (Clarivate Analytics, Thomson Reuters, Canada) and duplicates removed. These citations were independently reviewed for eligibility by two reviewers (JC and ZY) and the full texts of ambiguous articles retrieved if a consensus was not reached. When agreement could not be reached, a third author (PC) was consulted.

Two reviewers independently extracted the data from each trial into Excel, using a standardized form, and entered the combined data into RevMan 5.3 (Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The following data were extracted from each selected study: first author, publication year, total number of participants, age of patients, disease course, details of intervention and control groups, outcome indicators and reported adverse events. When consensus could not be reached, a third author (PC) was consulted.

Assessment of risk of bias
Two reviewers (JC and ZY) independently assessed the methodological quality of each included trial. A third reviewer (PC) helped to resolve disagreements. RevMan 5.3 was used to assess the risk of bias of each study using the following items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. We scored each criterion as showing a ‘high’, ‘low’ or ‘unclear’ risk.

Statistical analysis
All statistical analyses were conducted using RevMan 5.3. Studies were combined according to the types of intervention and assessment of the therapeutic effect of EA. Standardized mean difference (SMD) and 95% confidence intervals (CI) were calculated in the meta-analysis if the data were continuous. Risk estimates (odds ratio [OR]) and 95% CI were calculated if the data were dichotomous. Heterogeneity between studies was evaluated using the $\chi^2$ (chi-squared) test ($P < 0.05$ was considered significant) and the $I^2$ statistic. The standard $I^2$ test was used to assess the heterogeneity of the data; $\geq 50\%$ was considered to indicate a substantial level of heterogeneity.12 A random-effect model was used when there was significant heterogeneity; otherwise, sensitivity analysis and subgroup analysis were used to identify sources of heterogeneity.

Subgroup analysis. If there was significant heterogeneity among the included trials, we conducted subgroup analysis, based on patient age, severity of SUI, different EA acupoints and the course of treatment.

Sensitivity analysis. If factors influencing heterogeneity could not be identified using
subgroup analysis, we conducted a sensitivity analysis using the leave-one-out approach. Publication bias was evaluated using funnel plot analysis if a sufficient number of trials (10 trials) were identified; it was not evaluated when there were fewer than 10 studies in a group.

**Level of evidence.** The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework was used to assess the level of evidence and summarize each outcome. The level of evidence was classified as high, moderate, low or very low.

**Results**

**Search results**

Figure 1 shows details of the trial selection process. We retrieved 1150 articles, 125 from CNKI, 116 from WFDP, 50 from VIP, 77 from CBM, 306 from Web of Science, 299 from PubMed and 177 from the Cochrane Library. After initial screening of the abstracts and titles, 1022 studies were excluded because they were case reports, duplicates or meta-analyses; 128 articles were fully evaluated. Next, we excluded a further 89 articles, four of which compared the efficacy of EA with that of acupuncture, and 85 because they were of low quality, as evaluated using the Cochrane Handbook for Systematic Reviews of Interventions. The full texts of 39 articles were downloaded and assessed. Thirteen articles were excluded from further evaluation because they did not describe RCTs; 11 articles were excluded because they included duplicate data. Finally, 15 RCTs were analysed. Details of this strategy and a flow chart of the analysis are presented in Figure 1.

**Characteristics of included RCTs**

Table 1 shows the main study characteristics. A total of 1577 patients were included in the analysis: 790 in experimental groups and 787 in control groups. All included studies were published between 2004 and 2019. The age of included patients ranged from 26 to 84 years. All studies used EA with no other treatment interventions. Five studies compared EA with sham EA, with a pragmatic placebo needle used at sham acupoints. Three studies compared EA with oral midodrine hydrochloride, a synthetic sympathomimetic amine that is structurally similar to methoxamine, a relatively long-acting α1-selective adrenergic agonist. Three included studies compared EA with PFMT, which enhances the ability of the urinary tract sphincter to control urine and improves the symptoms of urinary incontinence by enhancing the function of the pelvic floor muscles. The other studies compared EA with traditional electrical stimulation, acupuncture alone or with MiNing (Chinese drug approval number: Z20026838), which is a Chinese diuretic drug. Fourteen studies had treatment durations between 4 and 12 weeks. Only one article reported a treatment duration of less than 4 weeks (10 days). Baseline characteristics and data were reported in each included study. Thirteen studies reported the therapeutic effect as the primary outcome, seven studies evaluated ICIQ-SF scores, two studies reported clinical symptom scores and two reported the frequency of urinary incontinence. Four studies reported adverse events. A summary of the studies is presented in Table 1.

**Assessment of risk of bias**

Two authors (JC and ZYZ) independently assessed the risk of bias for all included...
studies, using the Cochrane risk-of-bias tool, which evaluates random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other biases. As EA involves insertion of needles connected to low-voltage electricity, it is difficult to blind patients and physicians.

Thirteen papers described a proper method for, and details of, randomization, which was conducted using computerized
| Study               | Number of participants | Completed number | Age, years | Mean (±SD) | Experiment | Control | Duration | Outcomes (primary/secondary outcomes) | Course of disease | SUI screening tools                  | Adverse events |
|---------------------|------------------------|------------------|------------|------------|------------|---------|----------|--------------------------------------|------------------|-------------------------------------|----------------|
| Chen & Ma, 2015     | E: 45 C: 45            | E: 45 C: 45      | 19–70      | E: 47 ± 19 C: 45 ± 19 | EA         | Levator anti-muscle training | 8 weeks | Urine leakage degree; residual urine volume; therapeutic effect | E: 5.17 ± 3.12 (Y) C: 5.32 ± 3.35 (Y) | ICUD (Incontinence 4th Edition 2009) | None            |
| Bi, 2007            | E: 30 C: 30            | E: 30 C: 30      | 32–74      | E: 59.4 C: 57 | EA         | Promatine (midodrine hydrochloride) | 6–12 weeks | Therapeutic effect | I–15 (Y) | Female Urology | E: 0 C: 23 |
| Bao, 2014           | E: 30 C: 30            | E: 30 C: 30      | 40–76      | E: 56.2 ± 5.7 C: 56.7 ± 5.4 | EA         | Traditional electrical stimulation | 4 weeks | Total therapeutic effect; clinical symptom scores | E: 42.6 ± 11.8 (M) C: 43.1 ± 11.1 (M) | Modern Urology | None            |
| Chen et al., 2015   | E: 20 C: 18            | E: 20 C: 18      | 42–81      | E: 56.75 ± 9.44 C: 57.6 ± 10.01 | EA         | Traditional electrical stimulation | 4 weeks | Clinical symptom scores; therapeutic effect | E: 45.55 ± 26.74 (M) C: 30.67 ± 26.12 (M) | Campbell’s Urology: The Morden Guidance to Diagnosis and Treatment of Urology | None            |
| Xu et al., 2015     | E: 22 C: 21            | E: 22 C: 21      | 60–82      | E: 71.95 ± 7.59 C: 70.7 ± 8.53 | EA         | Sham EA | 4 weeks | 24-hour pad test; urodynamics test (ALPP, MUCP, MUP, SFL); superficial pelvic floor electrical stimulation; ICIQ-SF score; total therapeutic effect | E: 155.3 ± 35.21 (M) C: 152.47 ± 36.91 (M) | Campbell’s Urology; Diagnosis and Treatment for Urinary Incontinence | None            |
| He & Li, 2011       | E: 50 C: 50            | E: 50 C: 50      | 35–74      | 58.2       | EA         | Promatine (midodrine hydrochloride) | E: 30–60 days C: 30 days | Total therapeutic effect | I–5 (Y) | Female Urology | E: 0 C: 21 |
| Xu et al., 2014     | E: 35 C: 35            | E: 34 C: 32      | 55.06 ± 9.25 C: 55.14 ± 8.31 | EA         | Sham EA | 6 weeks | 1-hour pad test; frequency of urinary incontinence; ICIQ-SF score; adverse reactions; compliance | E: 60 (M) C: 72 (M) | ICUD (Incontinence 4th Edition 2009) | None            |
| Yang et al., 2004   | E: 40 C: 40            | E: 40 C: 40      | 30–62      | 45.6 C: 42.8 | EA         | Acupuncture alone | 10 days | Therapeutic effect | E: 3–36 (M) C: 2–24 (M) | International Continence Society | None            |
| Zheng et al., 2015  | E: 33 C: 33            | E: 33 C: 33      | 40–75      | 40–75      | EA         | PFMT | 4 weeks | ICIQ-SF score; 1-hour pad test; therapeutic effect | E: 3–82 (M) C: 4–79 (M) | EAU Guidelines on Urinary Incontinence | None            |
| Wang et al., 2016   | E: 90 C: 90            | E: 90 C: 90      | 35–70      | 52 ± 9 C: 51 ± 8 | EA         | PO (midodrine hydrochloride) | 4 weeks | ICIQ-SF score; 1-hour pad test; therapeutic effect | E: 3–82 (M) C: 4–79 (M) | Guidelines for the diagnosis and treatment of female stress urinary incontinence | None            |

(continued)
| Study            | Number of participants | Completed number | Age, years | Mean (±SD) | Experiment | Control  | Duration | Outcomes (primary/secondary outcomes) | Course of disease | SUI screening tools                        | Adverse events |
|------------------|------------------------|------------------|------------|------------|------------|----------|----------|--------------------------------------|------------------|------------------------------------------|----------------|
| He et al., 2016  | E: 20 C: 22            | E: 20 C: 22      | E: 40–75   | E: 56 ± 9  | C: 55 ± 8  | EA       | Sham EA | 6 weeks                              | UDI score; VAS score; nocturia; therapeutic effect | E: 6.3 ± 3.1 (Y) C: 6.5 ± 3.7 (Y) | ICUD (Incontinence 4th Edition 2009) | None          |
| Liu et al., 2016 | E: 42 C: 42            | E: 40 C: 39      | E: 55.81 ± 15.47 | E: 12 weeks | C: 24 weeks | EA       | PFMT    | 1-hour/24-hour pad test; average 24-hour urinary incontinence | E: 5.87 ± 3.61 (M) C: 6.12 ± 2.98 (M) | Incontinence Severity Index | None          |
| Shu et al., 2018 | E: 40 C: 40            | E: 40 C: 40      | E: 7 days  | E: 5.04 (M) C: 5.00 (M) | None | EA       | PO/MiNing capsule (Chinese drug approval number: Z20026838) | 1-hour pad test; therapeutic effect; ICIQ-SF score; IQOL score | Incontinence, 5th ICI | None          |
| Liu et al., 2017 | E: 252 C: 252          | E: 243 C: 239    | E: 40–75   | E: 54 ± 8.3 | C: 56.2 ± 8.4 | EA       | Sham EA | 6 weeks                              | ICIQ-SF score; self-evaluation of therapeutic effects | E: 4 C: 5 | None          |
| Xu et al., 2016  | E: 40 C: 40            | E: 39 C: 38      | E: 59.05 ± 7.91 | E: 6 weeks | C: 6 weeks | EA       | Sham EA | 1-hour pad test; ICIQ-SF score; self-evaluation of therapeutic effects | E: 5.04 (M) C: 5.00 (M) | None | None          |

SUI: stress urinary incontinence; E: experimental group; C: control group; EA: electroacupuncture; SD: standard deviation; PFMT: pelvic floor muscle training; IQOL: Incontinence Quality of Life Questionnaire; UDI: Urinary Distress Inventory; VAS: visual analogue scale; ALPP: abdominal leak point pressure; MUCP: maximum urethral closure pressure; MUP: major urinary protein; SFL: functional urethral length; Y: years; M: months; ICUD: International Consultation on Urological Diseases; EAM: European Association of Urology; ICI: International Continence Society.
randomization, a randomization list, the PROC PLAN procedure in SAS software (SAS Institute Inc., Cary, NC, USA) or sealed envelopes. Hence, these studies had a low risk of bias. Two studies were evaluated as having a high risk of bias, because they did not describe the randomization sequence (Figure 2).

Given the obvious nature of EA, most studies did not conduct blinding. Only five

Figure 2. Risk of bias graph.
studies, in which sham EA was used as the control intervention, performed blinding and therefore had a low risk of bias. All other studies had a high risk or an unclear risk of bias for the blinding of outcome assessment, as insufficient information was provided to assess whether or not the experimenters were blinded (Figure 3).

**Main findings**

**Therapeutic effects.** Thirteen studies reported therapeutic effects, including the ability to control urination, improvement of symptoms of discomfort, lack of catheterization requirement and residual urine volume <100 mL. As total heterogeneity was large, we used a sensitivity analysis to determine the heterogeneity values following elimination of studies one by one. Finally, the heterogeneity was reduced by 22% after eliminating the study by Chen and Ma (2015)\(^1\) (OR, CI = 5.64, 4.19–7.59; \(P < 0.01; I^2 = 22\%\)) (Figure 4). This may be because the evaluation standard used in the eliminated study was developed in-house, whereas in the other studies, patient SUI was rated using the Chinese version of the SUI guideline,\(^2\) the ICIQ-SF or a 4-point scale.

**ICIQ-SF scores.** Of the 15 studies, 6 reported ICIQ-SF scores. Analysis of their combined results demonstrated statistical significance (SMD, CI = -0.61, -0.74 to -0.48; \(P < 0.01; I^2 = 80\%\)), indicating that patients receiving EA had better ICIQ-SF scores than controls; however, the heterogeneity was considerable. Therefore, we carried out a sensitivity analysis. This showed a significant reduction in heterogeneity (SMD, CI = -0.48, -0.62 to -0.33; \(P < 0.01; I^2 = 32\%\)) when the study by Wang et al. (2016)\(^2\) was removed, indicating that this was probably the source of the heterogeneity (Figure 5).

**1-hour pad test.** Combined analysis of five studies reporting data from the 1-hour pad test indicated statistical significance (OR, CI = -4.14, -4.96 to -3.33; \(P < 0.01; I^2 = 78\%\)). Given the significant heterogeneity of these data, we conducted a subgroup analysis in which the studies were divided into two groups according to treatment duration (group one, \(\leq 4\) weeks; group two >4 weeks). However, the heterogeneity remained substantial. Next, we performed a sensitivity analysis to reduce the heterogeneity. Heterogeneity decreased after removal of the study by Wang et al. (2016);\(^2\) however, it remained considerable and we could not identify the differences among the other studies (Figure 6).
Adverse events

Only four studies reported adverse events. The study by He et al. (2016)\textsuperscript{20} reported that, in the control group, 21 of 50 patients had adverse events: 11 experienced xerostomia, 4 headache and 6 dizziness. Bi (2007)\textsuperscript{16} reported that in the control group, 11 patients experienced xerostomia, 7 dizziness, 4 headache and 1 patient experienced piloerection; however, there were no adverse events in the EA group. Xu et al. (2014)\textsuperscript{24} reported that 1 patient could not endure the pain in the EA group, and 2 patients developed haematomas. Liu et al. (2017)\textsuperscript{8} reported that 2 control patients experienced fatigue, 1 sharp pain, and 1 palpitations, whereas in the EA group, 4 patients developed
subcutaneous haematoma and 1 experienced fatigue.

**Publication bias**

We use RevMan to evaluate the bias in the total therapeutic effect of EA. A total of 13 trials were included, all from China. The distribution of included studies was asymmetric on both sides of the funnel plot, indicating the presence of publication bias in the therapeutic effect of EA (Figure 7).

**Discussion**

Modern medicine considers the brain and spinal cord to be high-level nerve centres that control urination. The urinary sphincter can be controlled by neuromodulation of urinary sphincter activity. Studies have shown that the sacral spinal nerves S2 and S4 play an important role in the process of urination. The detrusor activity of the bladder is dominated by the sacral nerves, including S4 and S2. EA may stimulate the skin or organ tissues, which are innervated by the sacral nerves. The nerve impulses then transfer to the striated muscles, which are innervated by S2 to S4. In addition, electrical stimulation of S3 is transmitted to the spinal cord, the nerve signals are transmitted to the thalamus, and then the thalamus integrates the impulses, which regulate bladder function.

One cause of SUI is an excessive or weak detrusor bladder function. The use of different EA frequencies (2 Hz and 100 Hz) can regulate the detrusor function to normal or near normal. Additionally, some studies have shown that EA stimulation of the acupoint Huiyang (BL 35) can stimulate the sacral autonomic nervous system, thereby enhancing the strength of the pelvic floor muscles. In addition, EA stimulates the perineal nerve, which regulates detrusor muscle function and controls urination.

Clarification of the effectiveness of EA compared with other conservative or drug therapies for patients with SUI is urgently required. Although many studies have shown that EA can have substantial therapeutic effects on SUI, its efficacy has not been confirmed scientifically. Here, we aimed to determine the effectiveness of EA by summarizing and evaluating its overall therapeutic effect and its influence on urine leakage and ICIQ-SF scores.

Thirteen studies comparing EA with other conservative or drug therapies reported a therapeutic effect of EA. All
found statistically significant benefits of EA therapies, according to the duration of treatment (≤4 weeks and >4 weeks). Six studies used ICIQ-SF scores and five used 1-hour urine leakage as primary outcomes. Our analysis showed that EA was superior to other therapies or drugs in terms of therapeutic effect, 1-hour urine leakage and ICIQ-SF scores. Analysis of therapeutic effects suggested that EA was highly effective compared with control treatments, without any accompanying heterogeneity for the first subgroup (≤4 weeks), but with substantial heterogeneity for the second subgroup (>4 weeks). The data on 1-hour urine leakage revealed a clear and significant reduction of urine leakage, with considerable heterogeneity; however, subgroup and sensitivity analyses reduced heterogeneity to within the acceptable range. Analysis of improvements in ICIQ-SF scores showed that EA was significantly superior to control treatments and that heterogeneity was reduced significantly by removal of the study by Wang et al. (2016); however, we did not identify differences among studies according to treatment time, intervention or course of disease.

Although this meta-analysis demonstrates that EA can improve and ameliorate SUI, more investigations are needed. More importantly, sample sizes were small in the included studies, with no multi-centre or multiblinded trials, and only four studies reported adverse events. In these, 49 control group patients and 7 EA group patients experienced adverse reactions, such as fatigue, sharp pain, palpitations and haematoma. We have yet to determine the mechanism by which EA ameliorates SUI; however, its effectiveness in relieving and improving symptoms has been confirmed by numerous studies and is widely accepted by clinicians and patients.

**Conclusion**

EA for women with SUI exhibited significant efficacy and safety for key outcomes, but additional large-scale, long-term RCTs with rigorous methodological quality are needed.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**ORCID iD**

Xiuhua Lai https://orcid.org/0000-0002-3171-1820

**References**

1. Abrams P, Cardozo L, Griffiths D, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. *Am J Obstet Gynecol* 2002; 187: 116–126.
2. Markland AD, Richter HE, Chyng-Wen F, et al. Prevalence and trends of urinary incontinence in adults in the United States. *J Urol* 2001; 186: 589–593.
3. Blanc B, Agostini A and Mullinger C. Surgical treatment of female stress urinary incontinence. *Bull Acad Natl Med* 2005; 189: 301–306.
4. Zhu L and Lang JC. The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China. *Menopause* 2009; 16: 831–836.
5. Horng SS, Huang N, Wu SI, et al. The epidemiology of urinary incontinence and it's influence on quality of life in Taiwanese middle-aged women. *Neurourol Urodyn* 2013; 32: 371–376.
6. National Collaborating Centre for Women’s and Children’s Health. *Urinary
incontinence: the management of urinary incontinence in women. London: RCOG Press, 2006, pp.906–911.

7. Lucas MG, Bosch RJL, Burkhard FC, et al. European Association of Urology guidelines on assessment and nonsurgical management of urinary incontinence—a randomized clinical trial. Actas Urol Esp 2013; 37: 199–213.

8. Liu ZS, Liu Y, Xu HF, et al. Effect of electroacupuncture on urinary leakage among women with stress urinary incontinence. JAMA 2017; 317: 2493–2501.

9. Hino K, Honjo H, Nakao M, et al. The effects of sacral acupuncture on acetic acid-induced bladder irritation in conscious rats. Urology 2010; 75: 730–734.

10. Yang W, Liu ZS, Peng WN, et al. Acupuncture for stress urinary incontinence in adults. Cochrane Database Syst Rev 2013; 7: 1181–1198.

11. Zhang MQ, Qin GZ, Wang DG, et al. Systematic evaluation and meta-analysis of acupuncture therapy for urinary calculus. Journal of Chengdu University of TCM 2019; 42: 75–80.

12. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.

13. Kloving A, Avery K, Sandvik H, et al. Comparison of two questionnaires for assessing the severity of urinary incontinence: the ICIQ-UI SF versus the incontinence severity index. Neurourol Urodyn 2009; 28: 411–415.

14. Xu HF, Liu BY, Wu JN, et al. A pilot randomized placebo controlled trial of electroacupuncture for women with pure stress urinary incontinence. PLoS One 2016; 11: e0150821.

15. Bao J. Clinical efficacy and mechanism of electroacupuncture vaginal nerve stimulation therapy for female stress urinary incontinence. Chinese and Foreign Medical Care 2014; 33: 4–5. doi: 10.16662.

16. Bi WL. Electroacupuncture treatment of female stress urinary incontinence. Chinese Journal of Traditional Chinese Medicine 2007; 6: 1284–1285. doi: 10.13193/j. archtcm.2007.06.197.biwl.090

17. Chen SX, Zhang FQ, Wang SY, et al. Sequential test of electroacupuncture yin nerve stimulation therapy for severe stress urinary incontinence. Acupuncture Clinical Journal 2015; 3: 3–5.

18. Chen YX and Ma RJ. Clinical observation on treatment of female stress urinary incontinence with electroacupuncture at Huiyang and Zhongyu points combined with scalp acupuncture. Shanghai Acupuncture Journal 2015; 12: 1159–1161.

19. He ZX and Li X. Electroacupuncture treatment of female mild to moderate stress urinary incontinence. Xinjiang Traditional Chinese Medicine 2011; 1: 19–21.

20. He EH, Chen YX, Tian HF, et al. Therapeutic effect of electroacupuncture on different acupuncture treatments for female stress urinary incontinence. Chinese Acupuncture & Moxibustion 2016; 4: 351–354. doi: 10.13703/j.0255-2930.2016.04.004.

21. Liu XR, Zang ZW, Li XL, et al. Efficacy observation of electro-acupuncturing at Zhongliao (BL33) and Huiyang (BL 35) on female stress urinary incontinence. Journal of Basic Chinese Medicine 2016; 7: 955–957.

22. Wang W, Jiang YM, Wang R, et al. Observations on the therapeutic effect of electroacupuncture on mild and moderate female stress incontinence. Shanghai Acupuncture Journal 2016; 1: 47–49.

23. Xu XH, Zhen P, Lv TT, et al. Comparison of electroacupuncture vaginal nerve stimulation and traditional acupuncture points on the treatment of acute stress urinary incontinence in elderly women. Chinese Journal of Gerontology 2015; 24: 7164–7166.

24. Xu HF, Du RS and Mo Q. A phase I clinical study on the efficacy of electroacupuncture for female patients with mild to moderate stress incontinence. Chinese Journal of Traditional Chinese Medicine 2014; 12: 3755–3758.

25. Yang TH, Zhou QY and Zhao KZ. Clinical study on electroacupuncture treatment of female stress urinary incontinence. Journal of Sichuan Traditional Chinese Medicine 2004; 6: 90–91.

26. Zheng HM, Xu SF, Yin P, et al. Observation on short-term and long-term therapeutic
effects of electro-acupuncture on mild and moderate stress urinary incontinence. *World Journal of Integrated Traditional Chinese and Western Medicine* 2015; 2: 191–209.

27. Shu F, Liu ZL and Zhang Z. Efficacy evaluation of electroacupuncture in the treatment of female stress urinary incontinence after TOT. *World Latest Medicine Information* 2018; 62: 33–34+37. doi: 10.19613/j.cnki.1671-3141.2018.62.014.

28. Lan Z. Guidelines for the diagnosis and treatment of female stress urinary incontinence. *Chinese Journal of Obstetrics and Gynecology* 2017; 52: 289–293. doi: 10.3760/cma.j.issn.0529-567x.2017.05.001.

29. Jo HM, Kim HS, Cho YW, et al. Two-year outcome of percutaneous bipolar radiofrequency neurotomy of sacral nerves S2 and S3 in spinal cord injured patients with neurogenic detrusor overactivity: a randomized controlled feasibility study. *Pain Physician* 2016; 19: 373–379.

30. Wang SY and Zhang SJ. Clinical efficacy and action mechanism of electrical pudendal nerve stimulation in treating female stress urinary incontinence. *Chinese Journal of Urology* 2013; 34: 575–578.

31. Han J, Ye XR, Meng XJ, et al. Regulation effect of electroacupuncture of different frequencies and acupoints on weakened detrusor function. *World Chinese Medicine* 2012; 7: 427–430.

32. Sun YC, Li JJ, Cheng XH, et al. Effect of electroacupuncture on different sites on detrusor pressure of detrusor areflexia neurogenic bladder after spinal cord injury. *Chinese Journal of Rehabilitation Theory and Practice* 2014; 734–737. doi: 10.3969/j.issn.1006-9771.2014.08.007.